Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: How to escape and move forward?

Pharmacogenomics

Volumn 14, Issue 11, 2013, Pages 1239-1242

  Lazzeri, Stefano ^a   Nardi, Marco ^a   Bocci, Guido ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

age related macular degeneration therapy; bevacizumab; polymorphisms; ranibizumab; VEGF

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VERTEPORFIN; PORPHYRIN; VEGFA PROTEIN, HUMAN;

ARMS2 GENE; CFH GENE; DRUG DOSE INCREASE; DRUG TISSUE LEVEL; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUBRETINAL NEOVASCULARIZATION; VEGF A GENE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; MACULAR DEGENERATION; PATHOLOGY;

HUMANS; INDIVIDUALIZED MEDICINE; MACULAR DEGENERATION; PHARMACOGENETICS; PORPHYRINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84882242755     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.100     Document Type: Review

References (20)

1. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431 (2006).
2. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432-1444 (2006).
3. Agosta E, Lazzeri S, Orlandi P et al. Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. Pharmacogenomics 13, 1037-1053 (2012).
4. Lazzeri S, Figus M, Orlandi P et al. VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics 14, 623-630 (2013).
5. Hagstrom SA, Ying GS, Pauer GJ et al. Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments trials (CATT). Ophthalmology 120, 593-599 (2013).
6. Chang W, Noh DH, Sagong M et al. Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population. Mol. Vision 19, 702-709 (2013).
7. Abedi F, Wickremasinghe S, Richardson AJ et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology 120, 115-121 (2013).
8. Boltz A, Ruiß M, Jonas JB et al. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration. Ophthalmology 119, 1615-1620 (2012).
9. Chen H, Yu KD, Xu GZ. Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis. PLoS ONE 7, e42464 (2012).
10. Wang VM, Rosen RB, Meyerle CB et al. Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration. Mol. Vision 18, 2578-2585 (2012).
11. Yamashiro K, Tomita K, Tsujikawa A et al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am. J. Ophthalmol. 154, 125-136 (2012).
12. Smailhodzic D, Muether PS, Chen J et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 119, 2304-2311 (2012).
13. Orlin A, Hadley D, Chang W et al. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 32, 4-9 (2012).
14. Funk M, Karl D, Georgopoulos M et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 116, 2393-2399 (2009).
15. Tong JP, Chan WM, Liu DT et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am. J. Ophthalmol. 141, 456-462 (2006).
16. Lai TY, Liu DT, Chan KP, Luk FO, Pang CP, Lam DS. Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial. Retina 29, 1218-1226 (2009).
17. Lin J, Wan L, Tsai YY et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am. J. Ophthalmol. 145, 1045-1051 (2008).
18. Brown DM, Chen E, Mariani A et al. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology 120, 349-354 (2013).
19. Bocci G, Loupakis F. The possible role of chemotherapy in antiangiogenic drug resistance. Med. Hypotheses 78, 646-648 (2012).
20. Leveziel N, Pelat T, Watier H et al. Detection of anti-ranibizumab antibodies among exudative AMD patients. Association for Research in Vision and Ophthalmology (ARVO) Meeting. Seattle, WA, USA, 5-9 May 2013 (Abstract 3170).